Cargando…

Evaluation of Antibody Properties and Clinically Relevant Immunogenicity, Anaphylaxis, and Hypersensitivity Reactions in Two Phase III Trials of Tralokinumab in Severe, Uncontrolled Asthma

INTRODUCTION: Tralokinumab is a monoclonal antibody (mAb) that neutralizes interleukin (IL)-13, a cytokine involved in the pathogenesis of asthma. OBJECTIVE: The objectives of this study were to characterize the potential immunogenic properties of tralokinumab and report data for anti-drug antibodie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carlsson, Mats, Braddock, Martin, Li, Yuling, Wang, Jihong, Xu, Weichen, White, Nicholas, Megally, Ayman, Hunter, Gillian, Colice, Gene
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2019
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6520328/ https://www.ncbi.nlm.nih.gov/pubmed/30649752 http://dx.doi.org/10.1007/s40264-018-00788-w

Ejemplares similares

Functionality and Performance of an Accessorized Pre-Filled Syringe and an Autoinjector for At-Home Administration of Tezepelumab in Patients with Severe, Uncontrolled Asthma
por: Alpizar, Sady, et al.
Publicado: (2021)

Application of structured statistical analyses to identify a biomarker predictive of enhanced tralokinumab efficacy in phase III clinical trials for severe, uncontrolled asthma
por: Gottlow, Mattis, et al.
Publicado: (2019)

CASCADE: a phase 2, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the effect of tezepelumab on airway inflammation in patients with uncontrolled asthma
por: Emson, Claire, et al.
Publicado: (2020)

Potential Risks Related to Modulating Interleukin-13 and Interleukin-4 Signalling: A Systematic Review
por: Braddock, Martin, et al.
Publicado: (2018)

Effect of Tezepelumab on Lung Function in Patients With Severe, Uncontrolled Asthma in the Phase 3 NAVIGATOR Study
por: Menzies-Gow, Andrew, et al.
Publicado: (2023)

Tralokinumab: First Approval
por: Duggan, Sean
Publicado: (2021)

Correction to: Tralokinumab: First Approval
por: Duggan, Sean
Publicado: (2021)

Correction to: Tralokinumab: First Approval
por: Duggan, Sean
Publicado: (2021)

Tezepelumab Reduces Exacerbations Across All Seasons in Patients with Severe, Uncontrolled Asthma: A Post Hoc Analysis of the PATHWAY Phase 2b Study
por: Corren, Jonathan, et al.
Publicado: (2021)

A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma
por: Piper, Edward, et al.
Publicado: (2013)

Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma with and without Nasal Polyposis: A Post Hoc Analysis of the Phase 2b PATHWAY Study
por: Emson, Claire, et al.
Publicado: (2021)

DESTINATION: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the long-term safety and tolerability of tezepelumab in adults and adolescents with severe, uncontrolled asthma
por: Menzies-Gow, Andrew, et al.
Publicado: (2020)

Population Pharmacokinetics of Tralokinumab in Adult Subjects With Moderate to Severe Atopic Dermatitis
por: Soehoel, Anders, et al.
Publicado: (2022)

Tezepelumab Efficacy in Patients with Severe, Uncontrolled Asthma with Comorbid Nasal Polyps in NAVIGATOR
por: Laidlaw, Tanya M, et al.
Publicado: (2023)

Pragmatic research and outcomes in asthma and COPD
por: Colice, Gene L
Publicado: (2012)

Tralokinumab pharmacokinetics and tolerability when administered by different subcutaneous injection methods and rates
por: Jain, Meena, et al.
Publicado: (2017)

Atopic dermatitis treated with tralokinumab and upadacitinib combination therapy: A case report
por: Lansang, Rafael Paolo, et al.
Publicado: (2023)

Docking analysis and the possibility of prediction efficacy for an anti-IL-13 biopharmaceutical treatment with tralokinumab and lebrikizumab for bronchial asthma
por: Nakamura, Yutaka, et al.
Publicado: (2017)

Therapeutic Potential of Tralokinumab in the Treatment of Atopic Dermatitis: A Review on the Emerging Clinical Data
por: Kelly, Katherine A, et al.
Publicado: (2022)

Outcomes of COVID-19 and Vaccination in Patients With Moderate to Severe Atopic Dermatitis Treated With Tralokinumab
por: Blauvelt, Andrew, et al.
Publicado: (2022)

Drug Hypersensitivity and Anaphylaxis in Cancer and Chronic Inflammatory Diseases: The Role of Desensitizations
por: Castells, Mariana
Publicado: (2017)

Allergy, Anaphylaxis, and Nonallergic Hypersensitivity: IgE, Mast Cells, and Beyond
por: Vitte, Joana, et al.
Publicado: (2022)

Real-World Experience with Tralokinumab in a Patient with Recalcitrant Atopic Dermatitis: A Case Report
por: Moennig, Eva, et al.
Publicado: (2022)

Safety and Efficacy of Tralokinumab in Older Adults With Moderate-to-Severe Atopic Dermatitis: A Secondary Analysis
por: Merola, Joseph F., et al.
Publicado: (2023)

Section 2. Exercise-Induced Bronchospasm: Albuterol versus Montelukast: Highlights of the Asthma Summit 2009: Beyond the Guidelines
por: Colice, Gene, et al.
Publicado: (2010)

Tiotropium in asthma: a systematic review
por: Befekadu, Elizabeth, et al.
Publicado: (2014)

NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma
por: Menzies-Gow, Andrew, et al.
Publicado: (2020)

HYPERSENSITIVENESS TO SOLUBLE SPECIFIC SUBSTANCES FROM YEAST-LIKE FUNGI : I. ANAPHYLAXIS
por: Kesten, H. D., et al.
Publicado: (1931)

Prevalence of Food-Hypersensitivity and Food-Dependent Anaphylaxis in Colombian Schoolchildren by Parent-Report
por: Beltrán-Cárdenas, Carlos Eduardo, et al.
Publicado: (2021)

Skin Barrier and Inflammation Genes Associated with Atopic Dermatitis are Regulated by Interleukin-13 and Modulated by Tralokinumab In vitro
por: TOLLENAERE, Maxim A. X., et al.
Publicado: (2021)

Dupilumab-Induced, Tralokinumab-Induced, and Belantamab Mafodotin–Induced Adverse Ocular Events—Incidence, Etiology, and Management
por: Mickevicius, Tomas, et al.
Publicado: (2023)

Pyrazolones metabolites are relevant for identifying selective anaphylaxis to metamizole
por: Ariza, Adriana, et al.
Publicado: (2016)

Antibiotic hypersensitivity in cystic fibrosis – Low frequency of anaphylaxis over 16 000 courses
por: Kowalik, Aleksandra, et al.
Publicado: (2022)

Real-Life Experience of Tralokinumab for the Treatment of Adult Patients with Severe Atopic Dermatitis: A Multicentric Prospective Study
por: De Greef, Axel, et al.
Publicado: (2023)

Efficacy and safety of tralokinumab in the treatment of atopic dermatitis: A systematic review and meta-analysis of randomized controlled trials
por: Zhao, Dan-Jie, et al.
Publicado: (2023)

STUDIES ON THE MECHANISM OF HYPERSENSITIVITY PHENOMENA : II. THE PARTICIPATION OF COMPLEMENT IN PASSIVE CUTANEOUS ANAPHYLAXIS OF THE ALBINO RAT
por: Osler, Abraham G., et al.
Publicado: (1957)

The ATAK complex (Adrenaline, Takotsubo, Anaphylaxis, and Kounis hypersensitivity -associated coronary syndrome) in neurological conditions
por: Kounis, Nicholas G., et al.
Publicado: (2016)

REVISITING HYPERSENSITIVITY REACTIONS TO THE MRNA COVID-19 VACCINE: TOLERANCE AFTER PREVIOUS HISTORY OF ANAPHYLAXIS
por: AlOtaibi, I., et al.
Publicado: (2022)

Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis: The Phase 3 ECZTRA 6 Randomized Clinical Trial
por: Paller, Amy S., et al.
Publicado: (2023)

Tralokinumab Efficacy Over 1 Year in Adults with Moderate-to-Severe Atopic Dermatitis: Pooled Data from Two Phase III Trials
por: Simpson, Eric L., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_88ub5vsna5lq8tfvqocijk1e61